FDA Issues 1st Stem Cell Warning Letter of 2018 to American CryoStem

SVF2

The FDA started off 2018 with a bang on the direct-to-consumer stem cell clinic front with a warning letter on January 3rd to American CryoStem, a firm involved in processing and distributing adipose stem cells. The company’s ATCELL™ adipose stem cell product was the focus of much of letter. The FDA indicated in the warning …

FDA Issues 1st Stem Cell Warning Letter of 2018 to American CryoStem Read More »